Treatment Characteristics of Kidney Stone Disease in Children

Kidney stone disease (KSD) is a disease caused by the formation of calculi in kidneys and other parts of the urinary tract. The rate of hospitalization of children with KSD worldwide is increasing. The adequate method of calculus extraction and further therapy according to calculus composition and metabolic disorders are crucial for effective treatment of patients with KSD and recurrence risk reduction. This review covers surgical (extracorporeal lithotripsy, percutaneous nephrolithotripsy, retrograde intrarenal surgery, ureterolithotripsy, laparoscopy, open surgery) and non-surgical (lithokinetic and litholytic) therapy. Special attention is paid to metaphylaxis, or recurrence prevention, and calculi formation. It is noted that medication of children with KSD can be aggravated by various adverse reactions, complexity in drugs dosages in children of first years of life. Moreover, all surgical methods are characterized by high risk of postoperative complications development. The relevance of KSD genetic nature in children, the role of lifestyle changes in disease development, the implementation of new drugs for metabolic disorders correction are presented in the article.

1. Mochekamennaya bolezn’: Clinical guidelines. Union of Pediatricians of Russia; Association of Medical Geneticists; 2021. (In Russ). Доступно по: https://www.pediatr-russia.ru/information/klin-rek/proekty-klinicheskikh-rekomendatsiy/МКБ%20_проект.pdf. Ссылка активна на 26.04.2021.

2. Mochekamennaya bolezn’ u detei: Clinical guidelines. Union of Pediatricians of Russia; 2016. (In Russ). Доступно по: http://astgmu.ru/wp-content/uploads/2018/10/Mochekamennaya-bolezn-u-detej-2016.pdf. Ссылка активна на 26.04.2021.

3. Gouru VR, Pogula VR, Vaddi SP, et al. Metabolic evaluation of children with urolithiasis. Urol Ann. 2018;10(1):94–99. doi: 10.4103/ua.ua_98_17

4. Alelign T, Petros B. Kidney Stone Disease: An Update on Current Concepts. Adv Urol. 2018;2018:3068365. doi: 10.1155/2018/3068365

5. Khan SR, Pearle MS, Robertson WG, et al. Kidney stones. Nat Rev Dis Primers. 2016;2(1):16008. doi: 10.1038/nrdp.2016.8

6. Samotyjek J, Jurkiewicz B, Krupa A. Surgical Treatment Methods of Urolithiasis in the Pediatric Population. Dev Period Med. 2018; 22(1):88–93.

7. Chaussy C, Brendel W, Schmiedt E. Extracorporeally induced destruction of kidney stones by shock waves. Lancet. 1980; 2(8207):1265–1268. doi: 10.1016/s0140-6736(80)92335-1

8. Talso M, Tefik T, Mantica G, et al. Extracorporeal shockwave lithotripsy: current knowledge and future perspectives. Minerva Urol Nefrol. 2019;71(4):365–372. doi: 10.23736/s03932249.19.03415-5

9. Sultan S, Umer SA, Ahmed B, et al. Update on Surgical Management of Pediatric Urolithiasis. Front Pediatr. 2019;7:252. doi: 10.3389/fped.2019.00252

10. Malikov ShG. Optimizatsiya rezhimov distantsionnoi udarno-volnovoi litotripsii u detei s urolitiazom. [dissertation]. Moscow; 2018. (In Russ).

11. He Q, Xiao K, Chen Y, et al. Which is the best treatment of pediatric upper urinary tract stones among extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy and retrograde intrarenal surgery: a systematic review. BMC Urol. 2019;19(1):98. doi: 10.1186/s12894-019-0520-2

12. Akin Y, Yucel S. Long-term effects of pediatric extracorporeal shockwave lithotripsy on renal function. Res Rep Urol. 2014;6: 21–25. doi: 10.2147/RRU.S40965

13. McAdams S, Shukla AR. Pediatric extracorporeal shock wave lithotripsy: Predicting successful outcomes. Indian J Urol. 2010; 26(4):544–548. doi: 10.4103/0970-1591.74457

14. Jee JY, Kim SD, Cho WY. Efficacy of Extracorporeal Shock Wave Lithotripsy in Pediatric and Adolescent Urolithiasis. Korean J Urol. 2013;54(12):865–869. doi: 10.4111/kju.2013.54.12.865

15. Bakri MH, Ismail EA, Ali MS, et al. Behavioral and emotional effects of repeated general anesthesia in young children. Saudi J Anaesth. 2015;9(2):161–166. doi: 10.4103/1658-354X.152843

16. Iqbal N, Assad S, Hasan A, et al. Extracorporeal shock wave lithotripsy in the treatment of pediatric nephrolithiasis: Comparison of the outcome between preschool and schoolgoing children: A single-center study. Transl Surg. 2016;1(4):91–94. doi: 10.4103/2468-5585.197491

17. Özgür BC, Irkilata L, Ekici M, et al. Pediatric extracorporeal shock wave lithotripsy: multi-institutional results. Urologia. 2016; 83(2):83–86. doi: 10.5301/urologia.5000053

18. Keshavamurthy R, Kumar S, Karthikeyan VS, et al. Tubeless Pediatric Percutaneous Nephrolithotomy: Assessment of Feasibility and Safety. J Indian Assoc Pediatr Surg. 2018;23(1):16–21. doi: 10.4103/jiaps.jiaps_22_17

19. Oner S, Akgul AK, Demirbas M, et al. Upper pole access is safe and effective for pediatric percutaneous nephrolithotomy. J Pediatr Urol. 2018;14(2):183e1–183e8. doi: 10.1016/j.jpurol.2017.12.013

20. Zeng G, Zhu W, Lam W. Miniaturised percutaneous nephrolithotomy: Its role in the treatment of urolithiasis and our experience. Asian J Urol. 2018;5(4):295–302. doi: 10.1016/j.ajur.2018.05.001

21. Hong Y, Xu Q, Huang X, et al. Ultrasound-guided minimally invasive percutaneous nephrolithotomy in the treatment of pediatric patients <6 years: A single-center 10 years’ experience. Medicine. 2018;97(13):e0174. doi: .10.1097/md.0000000000010174

22. Celik H, Camtosun A, Dede O, et al. Comparison of the results of pediatric percutaneous nephrolithotomy with different sized instruments. Urolithiasis. 2017;45(2):203–208. doi: 10.1007/s00240-016-0887-4

23. Öztürk H. Gastrointestinal system complications in percutaneous nephrolithotomy: a systematic review. J Endourol. 2014; 28(11):1256–1267. doi: .10.1089/end.2014.0344

24. Shah HN, Hegde SS, Mahajan AP, et al. Splenic injury: rare complication of percutaneous nephrolithotomy: report of two cases with review of literature. J Endourol. 2007;21(8):919–922. doi: 10.1089/end.2006.0451

25. Patil NA, Kundargi VS, Patil SB, et al. Conservative management of accidental gall bladder puncture during percutaneous nephrolithotomy. Cent Eur J Urol. 2014;67(2):191–192. doi: 10.5173/ceju.2014.02.art15

26. Dongol UMS, Limbu Y. Safety and Efficacy of Percutaneous Nephrolithotomy in Children. J Nepal Health Res Counc. 2017; 15(2):130–134. doi: 10.3126/jnhrc.v15i2.18192

27. Valecha NK, Bagheri F, Hassani SA, et al. Delayed Haematuria after Percutaneous Nephrolithotripsy and its Management. Med Sur Urol. 2017;6:3. doi: 10.4172/2168-9857.1000189

28. Chakraborty JN, Hatimota P. Same-day angiography and embolization in delayed hematuria following percutaneous nephrolithotomy: an effective, safe, and time-saving approach. Res Rep Urol. 2019;11:83–89. doi: 10.2147/RRU.S192175

29. Gadzhieva N, Malkhasyanb V, Akopyanc G, et al. Percutaneous nephrolithotomy for staghorn calculi: Troubleshooting and managingcomplications. Asian J Urol. 2020;7(2):139–148. doi: 10.1016/j.ajur.2019.10.004

30. Joshi MP, Zade PS, Doshi BH, Gavai MS. Paediatric ureterolithotripsy: Tips and tricks — Experience at a single center. Afr J Paediatr Surg. 2017;14(1):1–4. doi: 10.4103/0189-6725.226199

31. Yuruk E, Tuken M, Gonultas S, et al. Retrograde intrarenal surgery in the management of pediatric cystine stones. J Pediatr Urol. 2017;13(5):487. doi: 10.1016/j.jpurol.2017.01.015

32. Glybochko PV, Rapoport LM, Tsarichenko DG, et al. Gibkaya endoskopiya v diagnostike i lechenii zabolevanii verkhnikh mochevykh putei. Moscow: IndeksMed Media; 2019. (In Russ).

33. Lu P, Song R, Yu Y, et al. Clinical efficacy of percutaneous nephrolithotomy versus retrograde intrarenal surgery for pediatric kidney urolithiasis: A PRISMA-compliant article. Medicine. 2017; 96(43):e8346. doi: 10.1097/md.0000000000008346

34. Chernishev IV, Merinov DS, Epishov VA, et al. Retrograde intrarenal surgery for treatment of large and staghorn kidney stones. Experimental and clinical urology. 2012;(4):67–73 (In Russ).

35. Cassell A, Jalloh M, Ndoye M, et al. Surgical Management of Urolithiasis of the Upper Tract — Current Trend of Endourology in Africa. Res Rep Urol. 2020;12:225–238. doi: 10.2147/RRU.S257669

36. Starý D, Tůma J, Doušek R, et al. Laparoscopy at the pediatric surgery department for a five-year period. Rozhl Chir. 2018;97(3): 128–132.

37. Gao X, Fang Z, Lu Ch, et al. Management of staghorn stones in special situations. Asian J Urol. 2020;7(2):130–138. doi: 10.1016/j.ajur.2019.12.014

38. European Association of Urology. Guidelines 2018. Available online: https://uroweb.org/wp-content/uploads/EAU-Guidelines2018-compilation-of-all-guidelines.pdf. Accessed on April 26, 2021.

39. Kutluev MM, Safiullin RI, Mochalov KS. Time to recurrence after complete removal of calculi from different parts of the urinary system. Five-year follow-up study. Urologiia. 2018;(1):20–24.

40. Hollingsworth JM, Canales BK, Rogers MAM, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016; 355:i6112. doi: 10.1136/bmj.i6112

41. Kroczak T, Pace KT, Lee JY. Medical Expulsive Therapy: Worthwhile or Wishful Thinking. Curr Urol Rep. 2017;18(4):29. doi: 10.1007/s11934-017-0673-z

42. Atan A, Balcı M. Medical expulsive treatment in pediatric urolithiasis. Turk J Urol. 2015;41(1):39–42. doi: 10.5152/tud.2015.82856

43. Tsuda Y, Tatami S, Yamamura N, et al. Population pharm acokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Br J Clin Pharmacol. 2010;70(1):88–101. doi: 10.1111/j.1365-2125.2010.03662.x

44. Glina FP, Castro PMV, Monteiro GGR, et al. The use of alpha-1 adrenergic blockers in children with distal ureterolithiasis: a systematic review and meta-analysis. Int Braz J Urol. 2015;41(6):1049–1057. doi: 10.1590/s1677-5538.ibju.2015.0048

45. Velazquez N, Zapata D, Wang HHS, et al. Medical expulsive therapy for pediatric urolithiasis: Systematic review and metaanalysis. J Pediatr Urol. 2015;11(6):321–327. doi: 10.1016/j.jpurol.2015.04.036

46. Aldaqadossi HA, Shaker H, Saifelnasr M, Gaber M. Efficacy and safety of tamsulosin as a medical expulsive therapy for stones in children. Arab J Urol. 2015;13(2):107–111. doi: 10.1016/j.aju.2015.02.007

47. Nouri A, Hassali MA, Hamza AA. The role of corticosteroids in the management of kidney stones disease: a systematic review. Clin Pract. 2017;14(7):368–375. doi: 10.4172/clinicalpractice.1000133

48. European Association of Urology. Clinical guidelines 2019. (In Russ). Доступно по: http://asur-crimea.ru/wp-content/uploads/2019/09/89P-EAU_2019_Block_Disk.pdf. Ссылка активна на 26.04.2021.

49. Moudi E, Ghaffari R, Moradi A. Pediatric Nephrolithiasis: Trend, Evaluation and Management: A Systematic Review. J Pediatr Rev. 2017;5(1):e7785. doi: 10.17795/jpr-7785

50. McClinton S, Starr K, Thomas R, et al. Use of drug therapy in the management of symptomatic ureteric stones in hospitalized adults (SUSPEND), a multicentre, placebo-controlled, randomized trial of a calcium-channel blocker (nifedipine) and an α-blocker (tamsulosin): study protocol for a randomized controlled trial. Trials. 2014;15(1):238. doi: 10.1186/1745-6215-15-238

51. Pickard R, Starr K, MacLennan G, et al. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet. 2015;386(9991):341–349. doi: 10.1016/s0140-6736(15)60933-3

52. Copelovitch L. Urolithiasis in children: medical approach. Pediatr. Clin North Am. 2012;59(4):881–896. doi: 10.1016/j.pcl.2012.05.009

53. Kotsar’ AG. Matematicheskoe modelirovanie i algoritmizatsiya prognozirovaniya, diagnostiki, profilaktiki i lecheniya mochekamennoi bolezni. [dissertation]. Kursk; 2013. (In Russ).

54. Kiyatkin VA, Bobkov AD, Kazantsev SN, Shashlov SV. Complex physiobalno-treatment of patients with urgentium disease and urbum diatezy. Russian Journal of Rehabilitation Medicine. 2018;(2):37–45 (In Russ).

55. Konstantinova OV, Dutov VV, Katibov MI, et al. Experience in the use of mineral water «Naftusya» of Zbruchansk field in the treatment of patients with uroliths. Urologiia. 2013;(6):9–13. (In Russ).

56. Sheth KR, White JT, Perez-Orozco AF, et al. Evaluating Natural History and Follow Up Strategies for Non-obstructive Urolithiasis in Pediatric Population. Front Pediatr. 2018;6:353. doi: 10.3389/fped.2018.00353

57. Protoshchak VV, Paronnikov MV, Orlov DN, Kiselev AO. Medical and economic rationale for the use of modern methods of treating urolithiasis. Experimental and clinical urology. 2019;(3):12–18 (In Russ). doi: 10.29188/2222-8543-2019-11-3-12-18

58. Caudarella R, Vescini F. Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment. Arch Ital Urol Androl. 2009;81(3):182–187.

59. Skolarikos A, Straub M, Knoll T, et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015;67(4):750–763. doi: 10.1016/j.eururo.2014.10.029

60. Pepenin VR, Spiridonenko VV, Komarevtsev VN, et al. Rol’ tsitatnoi terapii pri lechenii uratnogo urolitiaza s pomoshch’yu maloinvazivnykh tekhnologii. Health of a man. 2011;(4):140–147. (In Russ).

61. Mir C, Rodriguez A, Rodrigo D, et al. Analysis of urine composition from split 24-h samples: use of 12-h overnight samples to evaluate risk factors for calcium stones in healthy and stone-forming children. J Pediatr Urol. 2020;16(3):371.e1–371.e7. doi: 10.1016/j.jpurol.2020.02.011

62. Nirumand MC, Hajialyani M, Rahimi R, et al. Dietary Plants for the Prevention and Management of Kidney Stones: Preclinical and Clinical Evidence and Molecular Mechanisms. Int J Mol Sci. 2018;19(3):765. doi: 10.3390/ijms19030765

63. Agarwal MM, Singh SK, Mavuduru R, Mandal AK. Preventive fluid and dietary therapy for urolithiasis: An appraisal of strength, controversies and lacunae of current literature. Indian journal of urology. Indian J Urol. 2011;27(3):310–319. doi: 10.4103/0970-1591.85423

64. Penido MGMG, de Sousa Tavares M. Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies. World J Nephrol. 2015;4(4):444–454. doi: 10.5527/wjn.v4.i4.444

65. Balueva LG. Kliniko-laboratornye osobennosti pielonefrita, protekayushchego s kristalluriei u detei, i usovershenstvovanie metodov lecheniya. [dissertation]. Perm’; 2014. (In Russ).

66. García-Perdomo HA, Solarte PB, España PP. Pathophysiology associated with forming urinary stones. Urol Colomb. 2016; 25(2):118–125. doi: 10.1016/j.uroco.2015.12.012

67. Akın Y, Uçar M, Yücel S. Current medical treatment in pediatric urolithiasis. Turk J Urol. 2013;39(4):253–263. doi: 10.5152/tud.2013.063

68. Cetin N, Gencler A, Tufan AK. Risk factors for development of urinary tract infection in children with nephrolithiasis. J Paediatr Child Health. 2020;56(1):76–80. doi: 10.1111/jpc.14495

69. Barataa SB, Ortiz C, Valetea S. Clinical epidemiological profile of 106 pediatric patients with urolithiasis in Rio de Janeiro, Brazil. Rev Paul Pediatr. 2018;36(3):261–267. doi: 10.1590/1984-0462/;2018;36;3;00009

70. Baştuğ F, Düşünsel R. Pediatric urolithiasis: causative factors, diagnosis and medical management. Nature reviews. Urology. 2012;9(3):138–146. doi: 10.1038/nrurol.2012.4

71. Chung HJ, Abrahams HM, Meng MV, Stoller ML. Theories of Stone Formation. In: Urinary Stone Disease. Current Clinical Urology. Stoller ML, Meng MV, eds. Humana Press; 2007.

72. Straub M, Strohmaier WL, Berg W, et al. Diagnosis and metaphylaxis of stone disease. World J Urol. 2005;23(5):309–323. doi: 10.1007/s00345-005-0029-z

73. Saenko VS, Gazimiev MA, Pesegov SV. The place of mineral water in the metaphylaxis of urolithiasis. Urologiia. 2016; (2 Suppl 2):87–94.

74. Kaygısız O. Metaphylaxis in Pediatric Urinary Stone Disease. In: Updates and Advances in Nephrolithiasis — Pathophysiology, Genetics, and Treatment Modalities. Layron Long; 2017. doi: 10.5772/intechopen.69982

75. Wagner C.A, Mohebbi N. Urinary pH and stone formation. J Nephrol. 2010;23 (16):165–169.

76. Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010;5(7):1277–1281. doi: 10.2215/CJN.08331109

77. Saenko VS, Lachinov EL, Zhantlisov DA, et al. Adjustment of urine pH as effective tool for successful metaphylaxis of urinary stone disease. Phytotherapy. Urologiia. 2020;(3): 104–110. (In Russ). doi: 10.18565/urology.2020.3.104-110

78. Manissorn J, Fongngern K, Peerapen P, Thongboonkerd V. Systematic evaluation for effects of urine pH on calcium oxalate crystallization, crystal-cell adhesion and internalization into renal tubular cells. Sci Rep. 2017;7(1):1798. doi: 10.1038/s41598-017-01953-4

79. Baatiah NY, Alhazmi RB, Albathi FA, et al. Urolithiasis: Prevalence, risk factors, and public awareness regarding dietary and lifestyle habits in Jeddah, Saudi Arabia in 2017. Urol Ann. 2020;12(1): 57–62. doi: 10.4103/UA.UA_13_19

80. Sas DJ. Dietary risk factors for urinary stones in children. Curr Opin Pediatr. 2020;32(2):284–287. doi: 10.1097/MOP.0000000000000886

81. Carvalho-Salemi J, Moreno L, Michael M. Medical Nutrition Therapy for Pediatric Kidney Stone Prevention, Part 3: Cystinuria. J Ren Nutr. 2017;27(3):e19–e21. doi: 10.1053/j.jrn.2017.02.002

82. Kovacevic L, Caruso JA, Lu H, et al. Urine proteomic profiling in patients with nephrolithiasis and cystinuria. Int Urol Nephrol. 2019;51(4):593–599. doi: 10.1007/s11255-018-2044-1

83. Szmigielska A, Pańczyk-Tomaszewska M, Borowiec M, et al. Vitamin D and Calcium Homeostasis in Infants with Urolithiasis. Adv Exp Med Biol. 2019;1133:75–81. doi: 10.1007/5584_2018_310

84. Amancio L, Fedrizzi M, Bresolin NL, Penido MG. Urolitíase pediátrica: experiência de um hospital infantil de cuidados ter ciários. J Bras Nefrol. 2016;38(1):90–98. doi: 10.5935/0101-2800.20160014

85. Scoffone CM, Cracco CM. Pediatric calculi: cause, prevention and medical management. Curr Opin Urol. 2018;28(5):428–432. doi: 10.1097/mou.0000000000000520

86. Milliner DS, Harris PC, Lieske JC. Primary Hyperoxaluria Type 3. 2015. In: GeneReviews®. Adam MP, Ardinger HH, Pagon RA, et al., eds. Seattle (WA): University of Washington, Seattle; 1993–2021. Available online: https://www.ncbi.nlm.nih.gov/books/NBK316514. Accessed on Aptil 26, 2021.

87. Bhasin B, Ürekli HM, Atta MG. Primary and secondary hyperoxaluria: Understanding the enigma. World J Nephrol. 2015; 4(2):235–244. doi: 10.5527/wjn.v4.i2.235

88. D’Alessandro C, Ferraro PM, Cianchi C, et al. Which Diet for Calcium Stone Patients: A Real-World Approach to Preventive Care. Nutrients. 2019;11(5):1182. doi: 10.3390/nu11051182

89. Sorensen MD, Kahn AJ, Reiner AP, et al. Impact of nutritional factors on incident kidney stone formation: a report from the WHI OS. J Urol. 2012;187(5):1645–1649. doi: 10.1016/j.juro.2011.12.077

90. Hernandez JD, Ellison JS, Lendvay TS. Current trends, evaluation, and management of pediatric nephrolithiasis. JAMA Pediatr. 2015;169(10):964–970. doi: 10.1001/jamapediatrics.2015.1419

91. Carvalho-Salemi J, Moreno L, Michael M. Medical Nutrition Therapy for Pediatric Kidney Stone Prevention, Part Two. J Ren Nutr. 2017;27(2):e11–e14. doi: 10.1053/j.jrn.2016.12.001

92. Prezioso D, Strazzullo P, Lotti T, et al. Dietary treatment of urinary risk factors for renal stone formation. Arch Ital Urol Androl. 2015;87(2):105-20. doi: 10.4081/aiua.2015.2.105

93. Makhmadzhonov DM, Sultonov ShR, Boboev ZA. Voprosy metafi laktiki nefrolitiaza u detey v endemicheskom ochage [Methaphylaxis of nephrolithiasis in children at the endemic region]. Vestnik Avitsenny [Avicenna Bulletin]. 2018;20(1):84–89. (In Russ).] doi: 10.25005/2074-0581-2018-20-1-84-89

94. Srivastava T, Alon US. Pathophysiology of hypercalciuria in children. Pediatr Nephrol. 2007;22(10):1659–1673. doi: 10.1007/s00467-007-0482-6

95. Choi JN, Lee JS, Shin JI. Low-dose thiazide diuretics in children with idiopathic renal hypercalciuria. Acta Paediatr. 2011; 100(8):e71–e74. doi: 10.1111/j.1651-2227.2011.02191.x

96. Phillips R, Hanchanale VS, Myatt A, et al. Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst Rev. 2015;(10):CD010057. doi: 10.1002/14651858.cd010057.pub2

97. Dickstein ES, Loeser WD. Triamterene Calculus. J Urol. 1985; 133(6):1019. doi: 10.1016/S0022-5347(17)49358-X

98. Krieger NS, Asplin JR, Frick KK, et al. Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria. J Am Soc Nephrol. 2015;26(12):3001–3008. doi: 10.1681/ASN.2014121223

99. Sharifian M, Hatamian B, Dalirani R. Evaluation of response to treatment with polycitra-K in urolithiasis of children. J Qazvin Univ Med Sci. 2011;14(4):28–33.

100. Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol. 2009;11(3):134–144.

101. Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. Nature reviews. Rheumatology. 2012; 8(10):610–621. doi: 10.1038/nrrheum.2012.144

102. Goldfarb DS. Potential Pharmacologic Treatments for Cystinuria and for Calcium Stones Associated with Hyperuricosuria. Clin J Am Soc Nephrol. 2011;6(8):2093–2097. doi: 10.2215/cjn.00320111

103. Leslie SW, Nazzal L, Sajjad H. Renal calculi (cystinuria, cystine stones). In: Pearls S, ed. Treasure Island, FL; 2020. p. 1.

104. Bawari S, Sah AN, Tewari D. Urolithiasis: An Update on Diagnost ic Modalities and Treatment Protocols. Indian J Pharm Sci. 2017;79(2): 164–174. doi: 10.4172/pharmaceutical-sciences.1000214

105. Fjellstedt E, Denneberg T, Jeppsson JO, et al. Cystine analyses of separate day and night urine as a basis for the management of patients with homozygous cystinuria. Urol Res. 2001;29(5): 303–310. doi: 10.1007/s002400100201

106. Konieczna I, Zarnowiec P, Kwinkowski M, et al. Bacterial urease and its role in long-lasting human diseases. Curr Protein Pept Sci. 2012;13(8):789–806. doi: 10.2174/138920312804871094